arrow
M

Michael Schmueck-Henneresse

humboldt university of berlin
H指数:19
被引数:1,549

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical development of tacrolimus-resistant regulatory T cells to enable simultaneous immunosuppression and immune regulation

他克莫司抵抗性调节性T细胞的临床开发以实现同时免疫抑制和免疫调节

2026-05-012
OAAI
Acute COVID-19 is associated with altered CD8 T-cells indicative of impaired ability to control Epstein–Barr virus reactivation

急性COVID-19与CD8 T细胞改变相关,表明其控制EB病毒再激活的能力受损

2026-04-200
OAAI
Lipid Nanoparticle mRNA Delivery Preserves CAR T-cell Cytotoxicity and Limits Exhaustion Compared to Electroporation

脂质纳米颗粒mRNA递送可维持CAR T细胞细胞毒性并限制其耗竭,相较于电穿孔。

2026-04-070
OAAI
Lung tumouroids as a testing platform for precision CAR T cell therapy

肺部肿瘤作为精密CAR T细胞治疗的测试平台

2026-01-210
OAAI
HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model
2025-10-130
OAAI
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells ( vol 24 , 89 , 2023)

结合不同的CRISPR核酸酶以实现同时的基因敲入和碱基编辑,可防止多基因编辑CAR T细胞中的易位(卷24,期89,2023)

2025-03-260
OA
Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer

CD3 epsilon基因编辑以重定向调节性T细胞用于过继性T细胞转移

2025-02-011
OAAI
Effector memory-type regulatory T cells display phenotypic and functional instability
2024-09-060
OAAI
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
2023-12-013
OAAI
In vitro and in vivo evidence that the switch from c for updates calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder
2022-12-015
PRE